SCHEMBL1701975

SCHEMBL1701975

O=C(O)NCOc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.54
MTNR1A P48039 2/20 0.52
MTNR1B P49286 2/20 0.52
RAB9A P51151 3/20 0.50
HPGD P15428 2/20 0.50
KMT2A Q03164 2/20 0.50
NPC1 O15118 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
RECQL P46063 3/20 0.47
TSHR P16473 2/20 0.47
MEN1 O00255 1/20 0.47
ALPL P05186 1/20 0.47
ALPI P09923 1/20 0.47
ALPG P10696 1/20 0.47
PKM P14618 1/20 0.47
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10450205 0.83 LMNA (0.47) CYP2C19CYP1A2
SCHEMBL6691222 0.83 MTNR1A (0.68) ALOX15MTNR1AMTNR1BRAB9AHPGD
SCHEMBL11410282 0.83 PARP10 (0.50) ALOX15MTNR1AMTNR1BRAB9AHPGD
SCHEMBL11408464 0.83 ALOX15 (0.50) ALOX15MTNR1AMTNR1BRAB9AHPGD
SCHEMBL3225336 0.82 NPC1 (0.69) RAB9AHPGDKMT2ANPC1SMN1; SMN2
SCHEMBL3446802 0.79 MTNR1A (0.73) MTNR1AMTNR1BRAB9AHPGDKMT2A
SCHEMBL5418397 0.79 THRB (0.51) ALOX15MTNR1AMTNR1BRAB9AHPGD
SCHEMBL9487171 0.79 MTNR1A (0.53) ALOX15MTNR1AMTNR1BRAB9AHPGD
SCHEMBL1027989 0.77 MTNR1A (0.51) ALOX15MTNR1AMTNR1BRAB9AHPGD
Anisole SCHEMBL28832564 0.77 MTNR1A (0.60) MTNR1AMTNR1BRAB9AKMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114040912-A Compounds for the treatment of kinase-dependent disorders 埃克塞里艾克西斯公司 2022-02-11 CN disclosed
EP-2566334-B1 CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS PROLYNX LLC (US) 2018-04-18 EP disclosed
EP-2566335-B1 CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM MACROMOLECULAR CONJUGATES PROLYNX LLC (US) 2016-06-29 EP disclosed
CN-103025165-B From the controlled release of macromolecular conjugates 普罗林科斯有限责任公司 2016-06-08 CN disclosed
US-8946405-B2 Controlled release from solid supports PROLYNX LLC (US) 2015-02-03 US disclosed
US-8754190-B2 Controlled release from macromolecular conjugates PROLYNX LLC (US) 2014-06-17 US disclosed
US-8703907-B2 Controlled drug release from dendrimers PROLYNX LLC (US) 2014-04-22 US disclosed
US-20130123487-A1 CONTROLLED RELEASE FROM SOLID SUPPORTS PROLYNX LLC (US) 2013-05-16 US disclosed
US-20130123461-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS PROLYNX LLC (US) 2013-05-16 US disclosed
US-20130116407-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES PROLYNX LLC 2013-05-09 US disclosed
CN-103025165-A Controlled release from macromolecular conjugates PROLYNX LLC 2013-04-03 CN disclosed
CN-103025164-A Controlled drug release from solid supports PROLYNX LLC 2013-04-03 CN disclosed
EP-2571496-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS Prolynx Llc (US) 2013-03-27 EP disclosed
EP-2566334-A1 CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS Prolynx Llc (US) 2013-03-13 EP disclosed
EP-2566335-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES Prolynx Llc (US) 2013-03-13 EP disclosed
WO-2011140376-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS PROLYNX LLC (US) 2011-11-10 WO disclosed
WO-2011140392-A1 CONTROLLED DRUG RELEASE FROM SOLID SUPPORTS PROLYNX LLC (US) 2011-11-10 WO disclosed
WO-2011140393-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES PROLYNX LLC (US) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123487-A1 CONTROLLED RELEASE FROM SOLID SUPPORTS SLC43A1, ABCB1, NAPA ALOX15 4647/4885MTNR1A 2133/4885MTNR1B 2435/4885
US-20130123461-A1 CONTROLLED DRUG RELEASE FROM DENDRIMERS SLC43A1, SLC47A1, SLC47A2 ALOX15 4753/4885MTNR1A 403/4885MTNR1B 338/4885
US-20130116407-A1 CONTROLLED RELEASE FROM MACROMOLECULAR CONJUGATES ABCB1, ABCB11, GUSB ALOX15 3821/4885MTNR1A 700/4885MTNR1B 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.